We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Penumbra (PEN) to Report Q1 Earnings: What's in the Cards?
Read MoreHide Full Article
Penumbra, Inc. (PEN - Free Report) is slated to report first-quarter fiscal 2021 results on May 4, after the closing bell.
In the last-reported quarter, the company’s earnings per share (EPS) of 42 cents surpassed the Zacks Consensus Estimate by 625%. Moreover, earnings surpassed the consensus estimate in three of the last four quarters and missed in one. The trailing four-quarter average surprise is 177.16%.
Let's see how things are shaping up prior to the announcement.
Factors at Play
Vascular
Similar to last quarter, strong demand for Lightning products is again expected to have driven the vascular segment’s top line in the first quarter. During the fourth-quarter earnings call, Penumbra confirmed the receipt of an indication from the FDA for Lightning 12 used for the treatment of pulmonary embolism or PE. Following the commercial launch, this product is expected to report full-quarter contribution on solid customer adoption. Moreover, in March, Penumbra launched Lighting 7 in the United States. This development is expected to have contributed to the top line in the first quarter.
Over the past few quarter, Penumbra continued to witness strong growth in its international business driven by growth in vascular thrombectomy and embolization products. In the last reported quarter, the company reported sequential growth in Lightning 12. With the business scenario remaining unchanged, we expect these to have continued in the to-be reported quarter as well, adding to the top line.
Moreover, Penumbra’s collaboration with Genesis MedTech Group in China is expected to have allowed Penumbra to gain a larger market share in China. We expect the collaboration to have positively contributed to first-quarter growth. During the fourth-quarter earnings call, Penumbra noted expectation of robust growth in Japan in 2021 and beyond, backed by growth opportunities in vascular thrombectomy and virtual reality. We expect the part of this projection to get reflected in first-quarter earnings results.
Neuro
Within the Neuro arm, Penumbra’s launch of BMX96 in late 2020 has been well received by physicians. We expect the continued adoption of BMX96 in the first quarter as well, adding to overall growth in the Neuro business. Similar to the previously-reported quarters, sequential growth is expected within Penumbra’s system for ischemic stroke management product/related support product, neuro embolization and access in the first quarter as well. Similar to the prior quarter, we expect continued sequential growth in Penumbra’s international Neuro business driven by strong performance across Europe, China and Asia-Pacific regions. However, the impact of the voluntary recall of JET seven XTRA FLEX might impede overall Neuro business growth.
Estimate Picture
For first-quarter fiscal 2021, the Zacks Consensus Estimate for total revenues of $153.3 million implies growth of 11.6% from the prior-year reported figure.
The consensus estimate for earnings per share is pegged at 11 cents compared with year-ago break-even earnings.
What Our Model Suggests
Our proven model does not conclusively predict an earnings beat for Penumbra this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat.
Earnings ESP: Penumbra has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3.
Stocks Worth a Look
Here are a few medical stocks worth considering as these have the right combination of elements to beat on earnings this reporting cycle.
The Cooper Companies, Inc. (COO - Free Report) has an Earnings ESP of +7.06% and a Zacks Rank of 2, at present.
Owens & Minor, Inc. (OMI - Free Report) has an Earnings ESP of +2.41% and a Zacks Rank of 2, at present.
Time to Invest in Legal Marijuana
If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027.
After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%
You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.
Image: Bigstock
Penumbra (PEN) to Report Q1 Earnings: What's in the Cards?
Penumbra, Inc. (PEN - Free Report) is slated to report first-quarter fiscal 2021 results on May 4, after the closing bell.
In the last-reported quarter, the company’s earnings per share (EPS) of 42 cents surpassed the Zacks Consensus Estimate by 625%. Moreover, earnings surpassed the consensus estimate in three of the last four quarters and missed in one. The trailing four-quarter average surprise is 177.16%.
Let's see how things are shaping up prior to the announcement.
Factors at Play
Vascular
Similar to last quarter, strong demand for Lightning products is again expected to have driven the vascular segment’s top line in the first quarter. During the fourth-quarter earnings call, Penumbra confirmed the receipt of an indication from the FDA for Lightning 12 used for the treatment of pulmonary embolism or PE. Following the commercial launch, this product is expected to report full-quarter contribution on solid customer adoption. Moreover, in March, Penumbra launched Lighting 7 in the United States. This development is expected to have contributed to the top line in the first quarter.
Over the past few quarter, Penumbra continued to witness strong growth in its international business driven by growth in vascular thrombectomy and embolization products. In the last reported quarter, the company reported sequential growth in Lightning 12. With the business scenario remaining unchanged, we expect these to have continued in the to-be reported quarter as well, adding to the top line.
Penumbra, Inc. Price and EPS Surprise
Penumbra, Inc. price-eps-surprise | Penumbra, Inc. Quote
Moreover, Penumbra’s collaboration with Genesis MedTech Group in China is expected to have allowed Penumbra to gain a larger market share in China. We expect the collaboration to have positively contributed to first-quarter growth. During the fourth-quarter earnings call, Penumbra noted expectation of robust growth in Japan in 2021 and beyond, backed by growth opportunities in vascular thrombectomy and virtual reality. We expect the part of this projection to get reflected in first-quarter earnings results.
Neuro
Within the Neuro arm, Penumbra’s launch of BMX96 in late 2020 has been well received by physicians. We expect the continued adoption of BMX96 in the first quarter as well, adding to overall growth in the Neuro business. Similar to the previously-reported quarters, sequential growth is expected within Penumbra’s system for ischemic stroke management product/related support product, neuro embolization and access in the first quarter as well. Similar to the prior quarter, we expect continued sequential growth in Penumbra’s international Neuro business driven by strong performance across Europe, China and Asia-Pacific regions. However, the impact of the voluntary recall of JET seven XTRA FLEX might impede overall Neuro business growth.
Estimate Picture
For first-quarter fiscal 2021, the Zacks Consensus Estimate for total revenues of $153.3 million implies growth of 11.6% from the prior-year reported figure.
The consensus estimate for earnings per share is pegged at 11 cents compared with year-ago break-even earnings.
What Our Model Suggests
Our proven model does not conclusively predict an earnings beat for Penumbra this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat.
Earnings ESP: Penumbra has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3.
Stocks Worth a Look
Here are a few medical stocks worth considering as these have the right combination of elements to beat on earnings this reporting cycle.
HCA Healthcare, Inc. (HCA - Free Report) has an Earnings ESP of +2.14% and a Zacks Rank of 1, at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Cooper Companies, Inc. (COO - Free Report) has an Earnings ESP of +7.06% and a Zacks Rank of 2, at present.
Owens & Minor, Inc. (OMI - Free Report) has an Earnings ESP of +2.41% and a Zacks Rank of 2, at present.
Time to Invest in Legal Marijuana
If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027.
After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%
You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.
Today, Download Marijuana Moneymakers FREE >>